iCAD Announces Positive Three-Year Data Using the Xoft System to Treat Skin Cancer Presented at ASTRO Data Demonstrates Effective Long-term Treatment with No Recurrences and Good Cosmetic Outcomes 2013 ASTRO Annual Meeting Business Wire NASHUA, N.H. & ATLANTA -- September 24, 2013 – Booth Number 2449 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that positive data using the Company’s Xoft^® Axxent^® Electronic Brachytherapy System^® to treat non-melanoma skin cancer (NMSC) were presented today at the American Society of Radiation Oncology’s (ASTRO) 55^th Annual Meeting being held from September 22-25, 2013 in Atlanta. The data show that at three years post-treatment, patients who had high dose rate (HDR) electronic brachytherapy with the Xoft System had good cosmesis, low toxicity levels and no recurrences. The Xoft System is the only electronic brachytherapy system with peer reviewed published clinical data supporting its use in skin cancer. More than 2,000 NMSC patients have been successfully treated with the Xoft System. Ajay Bhatnagar, MD, MBA, Cancer Treatment Services Arizona, Affiliate of 21^st Century Oncology, Adjunct Assistant Professor of Radiation Oncology, University of Pittsburgh School of Medicine and DermEbx, presented clinical outcomes data on 187 patients with 275 NMSC lesions treated with HDR electronic brachytherapy with surface applicators, using the Xoft System. One-year data on this patient cohort was published in the journal Brachytherapy in March/April 2013. “At three years post-treatment, we are continuing to see highly encouraging results with the Xoft System related to cosmesis and toxicity with no recurrences in non-melanoma skin cancer patients treated with HDR electronic brachytherapy,” said Dr. Bhatnagar. “We’ve found the Xoft System to be an ideal option for many patients, including the elderly, as the treatment schedule is convenient and it is significantly less invasive, allowing patients to complete their treatment plan and get back to their lives.” “We are pleased with the positive data and successful outcomes for those patients treated with the Xoft System for non-melanoma skin cancer. Dr. Bhatnagar’s study demonstrates the effectiveness of the technology three years post-treatment—a significant milestone for the radiation oncology community,” said Ken Ferry, President and CEO of iCAD. “Evidence is mounting in favor of this convenient, non-surgical, and effective treatment option that allows more skin cancer patients to receive radiation therapy.” About Non-Melanoma Skin Cancer NMSC, identified as either basal cell carcinoma or squamous cell carcinoma, is not only the most common type of skin cancer, it is the most common type of cancer in humans. These cancers commonly appear on sun-exposed areas of the body such as the face, ears, neck, lips, and backs of the hands. NMSC affects approximately 2.2 million Americans each year. About Xoft Axxent Electronic Brachytherapy System The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early stage breast cancer, endometrial cancer, cervical cancer and skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. A post-market study is underway to assess the safety and efficacy of Intraoperative Radiation Therapy with the Xoft System. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com. About iCAD, Inc. iCAD is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft System offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer, cervical cancer and endometrial cancer. For more information, call 877-iCADnow, or visit www.icadmed.com. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s ability to defend itself in litigation matters, the Company’s ability to identify a replacement for the Axxent FlexiShield Mini, the risks relating to the Company’s acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCAD’s and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov. Contact: For iCAD Kevin Burns, 937-431-7967 firstname.lastname@example.org or For iCAD investor relations Anne Marie Fields of LHA, 212-838-3777 x6604 email@example.com or For iCAD media inquiries Helen Shik of Schwartz MSL, 781-684-0770 iCAD@schwartzmsl.com
iCAD Announces Positive Three-Year Data Using the Xoft System to Treat Skin Cancer Presented at ASTRO
Press spacebar to pause and continue. Press esc to stop.